Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Wharton-Smith A, Horter SCB, Douch E, Gray NSB, James N, et al.
2021-12-04 • Trials
2021-12-04 • Trials
BACKGROUND Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF)...
Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, et al.
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...
Berry C, du Cros PAK, Fielding K, Gajewski S, Kazounis E, et al.
2022-06-13 • Trials
2022-06-13 • Trials
BACKGROUND Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9-24 months duration, have poor efficacy and...
Nyang'wa BT, LaHood AN, Mitnick CD, Guglielmetti L
2021-05-29 • Trials
2021-05-29 • Trials
When 2020 opened, approximately 11 million new tuberculosis (TB) cases and nearly 1.5 million TB-related deaths were predicted during the year. And, the gap between required and availabl...
BACKGROUND Lower extremity trauma during earthquakes accounts for the largest burden of disaster-related injuries. Insufficient pain management is common in resource-limited disaster...
Coldiron ME, Alcoba G, Ciglenecki I, Hitchings MD, Djibo A, et al.
2017-06-24 • Trials
2017-06-24 • Trials
Epidemics of meningococcal meningitis are common in the "African meningitis belt." Current response strategies include reactive vaccination campaigns, which are often organized too late ...
